Is Duvelisib a PI3K inhibitor?

Duvelisib (Duvelisib) is a PI3K inhibitor that mainly has inhibitory activity against PI3K-δ and PI3K-γ isoforms expressed in normal and malignant B cells. Duveliside induces growth inhibition and reduced viability in cell lines derived from malignantB cells and primary chronic lymphocytic leukemia (CLL) tumor cells. Duvelised inhibits several key cell signaling pathways, includingB cell receptor signaling and CXCR12-mediated malignant B cell chemotaxis. In addition, duvelised inhibits CXCL12-induced T cell migration and M-CSF and IL-4-driven macrophage M2 polarization.